Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to $1.7 million.

  • Oncology Institute's Depreciation & Amortization (CF) rose 953.59% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 1400.03%. This contributed to the annual value of $6.3 million for FY2024, which is 704.92% up from last year.
  • According to the latest figures from Q3 2025, Oncology Institute's Depreciation & Amortization (CF) is $1.7 million, which was up 953.59% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Depreciation & Amortization (CF) registered a high of $1.8 million during Q2 2025, and its lowest value of $777000.0 during Q1 2021.
  • In the last 5 years, Oncology Institute's Depreciation & Amortization (CF) had a median value of $1.3 million in 2023 and averaged $1.3 million.
  • In the last 5 years, Oncology Institute's Depreciation & Amortization (CF) skyrocketed by 4973.54% in 2023 and then plummeted by 736.16% in 2024.
  • Oncology Institute's Depreciation & Amortization (CF) (Quarter) stood at $920000.0 in 2021, then rose by 29.57% to $1.2 million in 2022, then soared by 32.3% to $1.6 million in 2023, then grew by 8.24% to $1.7 million in 2024, then grew by 0.94% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.8 million for Q2 2025, and $1.8 million during Q1 2025.